Literature DB >> 6360922

Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity.

J J Holst, T W Schwartz, N A Lovgreen, O Pedersen, H Beck-Nielsen.   

Abstract

The diurnal profiles of pancreatic glucagon, insulin, pancreatic polypeptide (PP), and enteroglucagon were studied in five obese non-diabetic subjects (195 +/- 11 per cent of ideal body weight) and in six age matched controls. All the subjects were served with ordinary mixed meals five times during the day. The obese subjects were normoglycemic but hyperinsulinemic. Both groups showed rapid increases in PP to all meals, but the PP-response was significantly impaired in the obese group during the first part of the day. Normal subjects showed significant enteroglucagon responses to all meals, and had elevated levels throughout the day. In obese subjects, levels and responses were much lower at all times. Pancreatic glucagon profiles were similar. It is concluded that the possible role of abnormalities of PP and enteroglucagon secretion in the pathogenesis of human obesity deserves further study.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6360922

Source DB:  PubMed          Journal:  Int J Obes


  18 in total

Review 1.  Potential use of exenatide for the treatment of obesity.

Authors:  Franco Folli; Rodolfo Guardado Mendoza
Journal:  Expert Opin Investig Drugs       Date:  2011-10-24       Impact factor: 6.206

Review 2.  Pancreatic signals controlling food intake; insulin, glucagon and amylin.

Authors:  Stephen C Woods; Thomas A Lutz; Nori Geary; Wolfgang Langhans
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

3.  Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying.

Authors:  E Näslund; P Grybäck; L Backman; H Jacobsson; J J Holst; E Theodorsson; P M Hellström
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

Review 4.  Gastrointestinal morbidity in obesity.

Authors:  Andres Acosta; Michael Camilleri
Journal:  Ann N Y Acad Sci       Date:  2014-03-06       Impact factor: 5.691

5.  Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions.

Authors:  B Schjoldager; P E Mortensen; J Myhre; J Christiansen; J J Holst
Journal:  Dig Dis Sci       Date:  1989-09       Impact factor: 3.199

6.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Authors:  A Flint; A Raben; A Astrup; J J Holst
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

7.  Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity.

Authors:  Elisabeth M H Mathus-Vliegen; Gerrit H de Groot
Journal:  Obes Surg       Date:  2013-05       Impact factor: 4.129

8.  Incretin response to a standard test meal in a rat model of sleeve gastrectomy with diet-induced obesity.

Authors:  Suleiman Al-Sabah; Fahad Alasfar; Ghanim Al-Khaledi; Reshma Dinesh; Mervat Al-Saleh; Habib Abul
Journal:  Obes Surg       Date:  2014-01       Impact factor: 4.129

9.  Alterations in circadian and meal-induced gut peptide levels in lean and obese rats.

Authors:  Alexander A Moghadam; Timothy H Moran; Megan J Dailey
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-15

Review 10.  Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes.

Authors:  Mitchel Tate; Aaron Chong; Emma Robinson; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.